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Abstract 1 
Although oligodendrocytes constitute a significant proportion of cells in the central nervous 2 
system (CNS), little is known about their intermediary metabolism. We have therefore 3 
characterised metabolic functions of primary oligodendrocyte precursor cell cultures at late 4 
stages of differentiation using isotope-labelled metabolites. We report that differentiated 5 
oligodendrocyte lineage cells avidly metabolise glucose in the cytosol and pyruvate derived 6 
from glucose in the mitochondria. The labelling patterns of metabolites obtained after 7 
incubation with [1,2-13C]glucose demonstrated that the pentose phosphate pathway (PPP) is 8 
highly active in oligodendrocytes (approximately 10% of glucose is metabolised via the PPP 9 
as indicated by labelling patterns in phosphoenolpyruvate). Mass spectrometry and magnetic 10 
resonance spectroscopy analyses of metabolites after incubation of cells with [1-13C]lactate or 11 
[1,2-13C]glucose, respectively, demonstrated that anaplerotic pyruvate carboxylation, which 12 
was thought to be exclusive to astrocytes, is also active in oligodendrocytes. Using [1,2-13 
13C]acetate we show that oligodendrocytes convert acetate into acetyl-CoA which is 14 
metabolized in the tricarboxylic acid cycle. Analysis of labelling patterns of alanine after 15 
incubation of cells with [1,2-13C]acetate and [1,2-13C]glucose showed catabolic oxidation of 16 
malate or oxaloacetate. In conclusion, we report that oligodendrocyte lineage cells at late 17 
differentiation stages are metabolically highly active cells that are likely to contribute 18 
considerably to the metabolic activity of the CNS.  19 
 20 
Keywords: Oligodendroglia, energy metabolism, glucose, 13C, mitochondria, glycolysis, 21 
acetate, pyruvate carboxylation.  22 
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Introduction 1 
Oligodendrocytes make up a large proportion of the cells in the central nervous system 2 
(CNS). Although oligodendrocytes are vulnerable to low energy conditions (Lyons and 3 
Kettenmann 1998; Yan and Rivkees 2006), their metabolic properties, including their glucose 4 
metabolism, have not been investigated in depth (Amaral et al. 2013). In contrast, the 5 
metabolic interactions between neurons and astrocytes, have received considerable attention 6 
since their discovery in the 1970’s (van den Berg and Garfinkel 1971). Specifically, the 7 
shuttling of glutamine - glutamate - γ-Aminobutyric acid (GABA) between astrocytes and 8 
neurons is thought to be fundamentally important for neuronal function. Because neurons 9 
themselves are unable to generate essential precursors of glutamate, GABA and aspartate, 10 
they depend on the supply of glutamine as a precursor from astrocytes for the production of 11 
neurotransmitters (glutamate in 90% of the synapses, and GABA in 5%) (Attwell and 12 
Laughlin 2001). In this context, glucose plays a central role as the key molecular building 13 
block that is used to synthesize glutamate, GABA and aspartate.  14 
 Glucose is primarily metabolised to pyruvate via glycolysis in the cytosol. Stepwise 15 
conversion of a single glucose molecule into two pyruvate molecules generates two molecules 16 
of ATP. These reactions are not oxygen dependent. Glucose metabolism can also take an 17 
alternative route via a biosynthetic pathway termed pentose phosphate pathway (PPP). This 18 
complex detour bypasses several steps of glycolysis. In the first, oxidative phase of the PPP, 19 
NADP+ is converted into NADPH. NADPH acts as a reducing agent that may participate in 20 
lipid and steroid synthesis or in the regeneration of glutathione and thioredoxin, which are 21 
involved in the cell’s defense mechanism against oxidative stress. In the second phase of the 22 
PPP, 5-carbon sugars are non-oxidatively synthetised. The PPP joins the glycolytic pathway 23 
at the level of glyceraldehyde-3-phosphate (GA3P) and fructose-6-phosphate (fructose-6P). 24 
 5 
Fructose-6P is subsequently converted into pyruvate, which constitutes the endpoint of both 1 
glycolysis and the PPP.  2 
 In the presence of oxygen, the pyruvate produced by glycolysis or by the PPP can be 3 
converted to acetyl CoA by the pyruvate dehydrogenase (PDH) complex, and subsequently 4 
metabolised in the mitochondrial tricarboxylic acid (TCA) cycle, to further produce ATP via 5 
coupling to the mitochondrial electron transport chain. Alternatively, pyruvate can be 6 
(reversibly) converted into lactate in the cytosol, which results in the production of NAD+ 7 
from NADH. Net synthesis of TCA cycle intermediates and related compounds, including 8 
glutamate and glutamine, depend on anaplerotic replenishment of intermediates in the TCA 9 
cycle. In the brain, this is mediated by pyruvate carboxylase (PC) (Patel 1974). Pyruvate 10 
carboxylation was shown to be absent in neurons, but present in astrocytes (Cesar and 11 
Hamprecht 1995; Hertz et al. 1980; Shank et al. 1985) (for review see Sonnewald and Rae 12 
2010). Consequently, neurons are thought to depend on astrocytes as an external source of 13 
glutamine for the production of neurotransmitters. Conversion of pyruvate by PC generates a 14 
'new' molecule of oxaloacetate. Oxaloacetate may subsequently condense with acetyl CoA to 15 
synthesise the TCA cycle intermediate citrate, which, after several steps, is converted to α-16 
ketoglutarate, from which glutamate can be formed by transamination or deamination. In a 17 
subsequent step, glutamine synthetase, which is known to be expressed in astrocytes 18 
(Martinez-Hernandez et al. 1977; Norenberg and Martinez-Hernandez 1979), is able to 19 
convert glutamate into glutamine  (see Figure 1 in Amaral et al. 2013).  20 
 In the grey matter, glutamate, released from neuronal synapses during glutamatergic 21 
neurotransmission, is mainly taken up by astrocytes (Gegelashvili and Schousboe 1997; 22 
Gegelashvili and Schousboe 1998). The drain of glutamate from signalling neurons is 23 
subsequently compensated by a reverse flow of glutamine from astrocytes back to the 24 
neurons. This cross flow of glutamate and glutamine is often referred to as the glutamate – 25 
 6 
glutamine cycle (McKenna et al. 2012) (see Figure 1 in Amaral et al. 2013). Because 1 
glutamine released by astrocytes also functions as a precursor for the production of the 2 
inhibitory neurotransmitter GABA via conversion to glutamate (Reubi et al. 1978; Sonnewald 3 
et al. 1993b), metabolic interactions between astrocytes and neurons are thought to consist of 4 
a glutamate-glutamine and a glutamine-glutamate-GABA cycle. 5 
 How can oligodendrocytes contribute to the metabolic interactions in the CNS? We 6 
have argued that, instead of being restricted to closed-loop interactions between astrocytes 7 
and neurons, inter-cellular shuttling of metabolites may occur between all three major cell 8 
groups of the CNS: neurons, astrocytes, and oligodendrocytes (Amaral et al. 2013). The 9 
limited understanding of the metabolic role of oligodendrocytes in the brain was further 10 
highlighted in two recent studies, which, for the first time, proposed a link between glycolytic 11 
metabolism in oligodendrocytes and axonal integrity and function (Funfschilling et al. 2012; 12 
Lee et al. 2012). 13 
 The aim of the present study was to elucidate basic metabolic pathways for glucose 14 
catabolism and the anaplerotic replenishment of TCA cycle intermediates in 15 
oligodendrocytes. For this purpose we incubated primary cultures enriched for mature 16 
oligodendrocytes in medium containing [1,2-13C]glucose, [1,6-13C]glucose, [1-13C]lactate or 17 
[1,2-13C]acetate and analysed cell extracts and medium using mass spectrometry or nuclear 18 
magnetic resonance (NMR) spectroscopy. We found that oligodendrocytes have extensive 19 
PPP activity. Furthermore, oligodendrocytes were able to anaplerotically replenish the TCA 20 
cycle, via pyruvate carboxylation, and cataplerotically recycle pyruvate. Our data also show 21 
that oligodendrocytes are able to convert [1,2-13C]acetate into acetyl CoA. Our results 22 
establish hallmarks of the cellular metabolism of oligodendrocytes under physiological 23 
conditions. They may also be useful for future studies investigating altered oligodendrocyte 24 
function and injury in diseases that involve glutamate toxicity and impaired mitochondria 25 
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function, including e.g. hypoxic-ischemic damage, and Multiple Sclerosis (MS) (Kostic et al. 1 
2013; Mifsud et al. 2014; Pitt et al. 2000; Simonishvili et al. 2013).   2 
 8 
Materials and Methods 1 
Materials 2 
Cell culture reagents were purchased from Sigma (Dorset, UK) - Dulbecco’s Modified Eagle’s 3 
Medium (DMEM), Minimum Essential Medium Eagle (MEM), L-Glutamine, poly-L-lysine 4 
(PLL), papain - or Life Technologies (Paisley, UK) - fetal bovine serum (FBS), penicillin-5 
streptomycin (pen-strep), trypsin-EDTA, phosphate buffered saline (PBS). 13C-labelled 6 
compounds were obtained from Cambridge Isotope Laboratories, MA, USA. The mass 7 
spectrometry derivatization reagents MTBSTFA (N-methyl-N- (tert - Butyldimethylsilyl) 8 
trifluoroacetamide), MSTFA (N-Methyl-N-(trimethylsilyl) trifluoroacetamide) and the t-9 
BDMS-Cl (tert-butyldimethylchlorosilane) were purchased from Regis Technologies, Inc. 10 
(Morton Grove, IL, USA). All other chemicals were of the purest grade available from Sigma 11 
(Dorset, UK).  12 
Preparation of primary oligodendrocyte precursor cell (OPC) cultures 13 
Primary mixed glia cultures were isolated from neonatal Sprague Dawley rat (postnatal day 14 
0–2) forebrains following a standard protocol (Baer et al. 2009). Pups were euthanized 15 
according to “Schedule 1” regulations from the Home Office Animal Procedures Committee 16 
UK. Cells were cultured for 10-15 days in DMEM supplemented with 10% FBS, 1% pen-17 
strep) and 4 mM glutamine, and kept under a humidified atmosphere at 37°C and 7% CO2. 18 
Oligodendrocyte precursor cells (OPCs) were subsequently isolated using a step-based shake-19 
off protocol and cultured in Sato’s medium on PLL-coated plates (Baer et al. 2009). To 20 
induce differentiation, OPCs were cultured in Sato’s medium supplemented with 0.5% fetal 21 
calf serum (FCS). The cell culture medium was replaced by fresh medium at day two of 22 
differentiation. For all in vitro experiments only cultures with >93% purity (determined based 23 
on O4 immunostaining) were used (Figure 1). Quantification of the number of GFAP-positive 24 
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cells after 5 days of differentiation, indicated that astrocytes comprised 7-10% of total cells 1 
(data not shown). 2 
Preparation of rat cortical astrocyte cultures 3 
Astrocytes were prepared from the same mixed glia cultures used for OPC isolation, 4 
following an adapted protocol described in (Amaral et al. 2014). After the shake-off (which 5 
eliminates microglia and most oligodendrocytes from the cultures), the remaining cells, 6 
highly rich in proliferative astrocytes, were seeded into new T75 flasks (1:3 dilution) using 7 
DMEM supplemented with 10% (v/v) FBS, 4 mM glutamine, and 1% (v/v) pen-strep and 8 
allowed to reach confluence (approx. 5-7 days). Then, cells were collected with trypsin-9 
EDTA and seeded in 6 well plates at a density of 5x104 cells/well for the [1-13C]lactate 10 
experiments. Experiments were performed when cells reached confluence. 11 
 12 
Incubations with 13C labelled compounds 13 
Mature OPC cultures (after 5 days in differentiation medium) were cultured in 6 well plates at 14 
a cell density of 4x105 cells/well. Prior to incubation, cells were washed once with PBS and 15 
incubated with 2 ml Sato’s medium prepared from a glucose, glutamine and pyruvate-free 16 
DMEM (Sigma D5030) supplemented with 0.5% FCS and 2 mM [1,6-13C]glucose, 2 mM 17 
[1,2-13C] glucose + 1 mM glutamine, 2 mM [1,2-13C]acetate + 1 mM glutamine or 5 mM [1-18 
13C]lactate + 2 mM glucose + 1 mM glutamine for 24h. Astrocytes were washed once with 19 
PBS and incubated with 2 ml DMEM (Sigma D5030) supplemented with 4 mM [1-13C]lactate 20 
+ 2 mM glucose, 1 mM glutamine, 1% pen-strep and 1% FBS for 24h. Samples of medium 21 
were collected before and after the incubation period and subsequently analysed by mass 22 
spectrometry. After the 24h incubation period, cells were washed twice with cold PBS and the 23 
intracellular metabolites extracted with 70% ethanol (Amaral et al. 2014). Astrocyte cultures 24 
were also incubated for 24h in 2 ml DMEM containing 2 mM D-glucose, 1 mM glutamine, 25 
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1% pen-strep and 1% FBS in order to determine glucose consumption and lactate production 1 
rates after 24h. Experiments were performed on 9 - 12 samples, which derived from a 2 
minimum of three independently generated cultures.  3 
 4 
Immunocytochemistry 5 
OPCs were seeded on PLL-coated glass coverslips on 24 well plates (7x104 cells/well) and 6 
fixed after 5 days of differentiation with 4% paraformaldehyde. Cells were stained with an 7 
anti-O4 mouse monoclonal antibody (1:200; Sigma, Dorset, UK), anti-myelin basic protein 8 
(MBP) rat polyclonal antibody (1:300; Merck Millipore, Hertfordshire, UK) and anti-glial 9 
fibrillary acidic protein (GFAP) rabbit polyclonal antibody (1/500; Dako, Glostrup, 10 
Denmark). Secondary antibodies conjugated with Alexa Fluor 488 and Alexa Fluor 555 were 11 
used to visualize positive cells (1:500; Life Technologies, Paisley, UK). Following 12 
immunocytochemistry, cells were mounted with Prolong gold antifade mounting medium 13 
(Life Technologies, Paisley, UK). To assess purity and differentiation of oligodendroglia 14 
lineage cells in the cultures, the percentage of O4-, MBP- and GFAP- positive cells relative to 15 
>100 DAPI-stained nuclei per experiment in randomly selected eye fields was determined. 16 
Cells were visualized and digitized at ambient temperature on an LSM 700 confocal 17 
microscope (Zeiss, Thornwood, NJ) at 20× magnification using Zen Application software 18 
(Zeiss). 19 
 20 
Assessment of cell viability  21 
To assess cell viability under the different experimental conditions, the Dead End™ 22 
Fluorometric TUNEL System Kit (Promega, Madison, WI) was used according to the 23 
manufacturer’s instructions. Images of the stained cells were obtained using an INCell 24 
Analyzer 2200 Imaging System (GE Healthcare Life Sciences) and processed using the 25 
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ImageJ software. 10 random fields were acquired per condition using a magnification of 20x. 1 
Image analysis and quantification was performed on CellProfiler, a cell image analysis 2 
software developed by the BROAD Institute. The number of DAPI-positive nuclei (total 3 
number of cells) and the number of TUNEL-positive nuclei were automatically counted, and 4 
the results presented as percentage of apoptotic nuclei of all DAPI-positive nuclei. 5 
 6 
Glucose and lactate analyses 7 
Glucose and lactate levels in the cell culture medium were analysed at the Core Biochemical 8 
Assay Laboratory, Clinical Biochemistry, Addenbrooke’s Hospital using automated assays on 9 
a Siemens Dimension RxL analyser. The rate of glucose and lactate net change relative to 10 
cells over time (µmol/106 cells/24h) was calculated by subtracting the value measured at the 11 
end of the experiment (T=24h) from the one measured in a sample of medium collected at the 12 
onset of the incubation, and dividing the resulting value by the amount of cells in each 13 
experiment, multiplied by the experimental volume (2 ml). For oligodendrocyte cultures, the 14 
cell number considered was the cell number at plating since these cells do not proliferate. For 15 
astrocyte cultures (which proliferate to some extent), the cell number considered was 16 
determined at the end of the experiment, after collection of cells from two sample wells using 17 
trypsin-EDTA. 18 
High performance liquid chromatography (HPLC) 19 
HPLC was used to quantify the total amounts of amino acids in samples of cell extracts and 20 
medium. Samples were lyophilized and resuspended in 0.01M HCl and subsequently 21 
derivatized with o-phtaldialdehyde (Geddes and Wood 1984) using an automated method 22 
prior to injection into the HPLC column. The amino acid components were separated with a 23 
ZORBAX SB-C18 (4.6 × 150 mm, 3.55 micron) column from Agilent Technologies (Palo 24 
Alto, CA). As eluents, a mixture of 50 mM sodium phosphate buffer (pH 5.9) with 2.5% 25 
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tetrahydrofurane and a mixture of methanol (98.75%) with tetrahydrofurane (1.25%) were 1 
used. The samples were analyzed using a Hewlett Packard 1100 System (Agilent 2 
Technologies, Palo Alto, CA) with fluorescence detection. Amino acid concentrations were 3 
determined by comparison to a calibration curve of standard solutions of amino acids run after 4 
every 12 samples (Amaral et al. 2014). 5 
Gas Chromatography-Mass Spectrometry (GC-MS) 6 
For analysis of percent enrichment of 13C in lactate, amino acids (alanine, aspartate, glutamate 7 
and glutamine) and TCA cycle intermediates (citrate and malate) after incubation with 8 
different 13C labelled substrates, cell extracts and samples of medium were lyophilized and 9 
resuspended in 0.01M HCl. To move the metabolites of interest into the organic phase in their 10 
acid form, the pH was adjusted to pH<2 with 6 M HCl. Samples were dried under 11 
atmospheric air (50 °C), and metabolites were derivatised with MTBSTFA in the presence of 12 
1% t-BDMS-Cl (Mawhinney et al. 1986). The protocol used for analysis of the glycolytic 13 
intermediates phosphoenolpyruvate (PEP) and 3-phosphoglycerate (3PG) was based on the 14 
protocol reported by Hofmann et al. (2008). Derivatization was performed using a mixture of 15 
MSTFA + 1% trimethylchlorosilane (TMS) and acetonitrile. The samples were analyzed on 16 
an Agilent 6890 gas chromatograph connected to an Agilent 5975B mass spectrometer 17 
(Agilent Technologies, Palo Alto, CA). The parent ion (M) and atom percent excess for one 18 
13C atom (M+1) values for 3PG, PEP, alanine, aspartate, lactate, citrate and glutamate were 19 
calculated from the GC-MS data using the MassHunter software supplied by Agilent (Agilent 20 
Technologies, Palo Alto, CA) and correcting for the naturally abundant 13C by using non-21 
enriched standards (Biemann 1962).  22 
13C and 1H Nuclear Magnetic Resonance (NMR) Spectroscopy 23 
13C NMR spectroscopy was used to identify the synthesis of particular labelled isotopologues 24 
from [1,2-13C]glucose metabolism due to the ability of this technique to distinguish between 25 
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the different carbon positions that are labelled in one molecule. For example, 13C NMR 1 
spectroscopy enabled to distinguish between the presence of [2,3-13C]glutamate (synthesized 2 
via pyruvate carboxylation) and [1,2-13C]glutamate (synthesized via PDH; see below for 3 
further details). On the other hand, GC-MS is a more sensitive method that provides 4 
information about 13C enrichment above natural abundance but lacks the specificity of NMR 5 
spectroscopy, as it does not provide information about the location of the 13C label. GC-MS, 6 
as applied in the present study, only enables to distinguish between species that have a 7 
different number of 13C labelled carbons. All NMR samples were analysed using a QCI 8 
CryoProbe™ 600MHz (for proton) ultrashielded Plus magnet (Bruker BioSpin GmbH, 9 
Reinstetten, Germany). 1H NMR spectra were acquired using a pulse angle of 90°, 12 kHz 10 
spectral width with 66 data points, acquisition time of 2.66 seconds, relaxation delay of 10 11 
seconds and 128 scans. These spectra were used to quantify the amount of glutamate for 12 
correction of natural abundance of [4-13C]glutamate (to be used in the calculation of 13 
contribution of the PPP to [4-13C]glutamate synthesis). Proton decoupled 13C NMR spectra 14 
were obtained on the same instrument using a 30° pulse angle and 30 kHz spectral width with 15 
98 000 data points employing an acquisition time of 1.65 seconds and a relaxation delay of 16 
0.5 seconds. The number of scans needed to obtain an appropriate signal to noise ratio was 17 
210 000. TopSpin™ 3.0 software (Bruker BioSpin GmbH, Reinstetten, Germany) was used 18 
for acquisition, integration, and quantification. Relevant peaks in the spectra were assigned 19 
and quantified from the integrals of the peaks using ethylene glycol as an internal standard 20 
with known amount of 13C. Corrections for natural abundance as well as nuclear Overhauser 21 
enhancement and relaxation effects, relative to the internal standard, were applied to all 22 
relevant integrals from 13C spectra.  23 
Statistical analysis 24 
 14 
Statistical analysis was conducted using unpaired two-tailed Student t-tests (confidence 1 
interval=95%).  2 
3 
 15 
Results 1 
Characterisation of late differentiation-stage oligodendrocyte lineage cells in vitro 2 
To study metabolic reactions in mature oligodendroglia cultures, highly enriched primary rat 3 
OPCs (Figure 1A) were differentiated in Sato’s differentiation medium. At 5 days of 4 
differentiation the cells displayed the characteristically branched morphology of late 5 
oligodendrocyte lineage cells with approximately 65% of the cells expressing MBP (Figure 6 
1B). To investigate the relative activity of different metabolic pathways in mature 7 
oligodendrocytes, cells were incubated with one of the following 13C-labelled substrates: [1,6-8 
13C]glucose, [1,2-13C]glucose, [1-13C]lactate or [1,2-13C]acetate.   9 
 10 
Differentiated oligodendrocyte lineage cells display a significant activity of the pentose 11 
phosphate pathway  12 
To investigate the relative activity of the glycolytic pathway versus the PPP, [1,2-13C]glucose 13 
was added to the medium (Brekke et al. 2014; Dusick et al. 2007). Following 24h of 14 
incubation, cell extracts were collected and analysed using GC-MS and 13C and 1H NMR 15 
spectroscopy. If [1,2-13C]glucose is metabolised via the glycolytic pathway,  [2,3-13C]3PG, 16 
[2,3-13C]PEP and [2,3-13C]pyruvate are formed (Figure 2A). [2,3-13C]pyruvate can enter the 17 
mitochondria to be converted into [1,2-13C]acetyl CoA. Condensation of [1,2-13C]acetyl CoA 18 
with unlabelled oxaloacetate leads to the formation of the TCA cycle intermediate [1,2-19 
13C]citrate and then, following several steps, α-[4,5-13C]ketoglutarate, which is subsequently 20 
converted into [4,5-13C]glutamate. [1,2-13C]glucose metabolism via the PPP gives rise to [3-21 
13C]3PG, [3-13C]PEP, [3-13C]pyruvate and [2-13C]acetyl CoA (Figure 2B). [2-13C]acetyl CoA 22 
can then be converted into [4-13C]glutamate via the TCA cycle (Figure 2B). 23 
 Because PEP and 3PG are localized downstream of the intersection between 24 
glycolysis and the PPP, their 13C isotopologues can be used to calculate the ratio between 25 
 16 
glycolysis and the PPP. Analysis of PEP and 3PG enables detection of isotopologues that 1 
derive from the re-entry of metabolic intermediates (fructose-6P and GA3P) into glycolysis 2 
from the PPP. The intermediates of the PPP lose the 13C in the C1 position via 3 
decarboxylation of [1,2-13C]gluconate-6-phosphate by 6-phosphogluconate dehydrogenase 4 
and 1/3 of the molecules will re-enter glycolysis with only one labelled (M+1) carbon instead 5 
of two (M+2) – see Figure 2 and (Brekke et al. 2012) for further details. Based on GC-MS 6 
results, the M+2/M+1 ratios of PEP and 3PG were calculated, indicating that 10-15% of 7 
glucose is metabolised via the PPP in mature oligodendrocytes (Figure 2C). Of note, this ratio 8 
is likely to under-estimate the contribution of the PPP (for details see Brekke et al. 2012). 9 
An alternative way to investigate the relative contribution of glycolysis and PPP to 10 
glucose metabolism is to apply 13C NMR spectroscopy to differentiate between [4,5-13C] and 11 
[4-13C]glutamate (Figure 2D). In the 13C NMR spectrum glycolysis-derived [4,5-12 
13C]glutamate is represented as a doublet in the C-4 region of glutamate (34.5 ppm), whereas 13 
PPP-derived [4-13C]glutamate is represented as a singlet. The contribution of glucose 14 
metabolized via the PPP relative to glucose metabolized via glycolysis to the total glutamate 15 
synthesis was calculated by dividing the area of the [4-13C]glutamate peak (after correction 16 
for natural abundance using 1H NMR spectroscopy) by the area of the doublet peak [4,5-17 
13C]glutamate. We found that 10% ± 0.2% (mean ± s.e.m.; n=3) of the total glutamate comes 18 
from glucose metabolized in the PPP. Our results confirm that the PPP is active in 19 
oligodendrocytes and that it contributes to glutamate synthesis. 20 
Evidence for PDH and mitochondrial activity in oligodendrocytes 21 
To investigate the extent of oxidative metabolism in oligodendrocytes, cells were incubated 22 
with 13C-labelled glucose or [1,2-13C]acetate for 24h (for labelling patterns see Figure 3A, B). 23 
We confirmed that after 24h, all [1,6-13C]glucose-derived metabolites, except for glutamine, 24 
 17 
reached a steady-state of labelling (Supplementary Figure 1). Hence, we decided to 1 
investigate labelling patterns in cell lysates after 24 in all subsequent experiments. Assessing 2 
cell viability using TUNEL staining showed no differences between the various experimental 3 
conditions (Figure 3C). Metabolism of [1,6-13C]glucose yields two molecules of [3-4 
13C]alanine and [3-13C]pyruvate. The latter is then converted into [2-13C]acetyl CoA, which 5 
can condense with non-labelled oxaloacetate to form mono-labelled (M+1) compounds in the 6 
first turn of the TCA cycle (described in Figure 3A). [2-13C]acetyl CoA can also condense 7 
with labelled oxaloacetate and give rise to the formation of double-labelled (M+2) 8 
compounds in a combination of the first and second turn of the cycle (Figure 3A). GC-MS 9 
analysis of cell extracts incubated with [1,6-13C]glucose (Figure 3D), showed that 10 
mitochondrial metabolism was prominent in mature oligodendrocytes. TCA cycle 11 
intermediates and amino acids were highly enriched ranging from 15-25% in citrate, malate, 12 
glutamate and glutamine and 10% in aspartate (Figure 3D). Moreover, a substantial 13 
enrichment was also observed with M+2 isotopologues and even M+3 (data not shown), 14 
typical of the second and third turns of the TCA cycle (see Figure 3D). However, the second 15 
turn of the TCA cycle is underestimated since labelled oxaloacetate can condense with 16 
unlabelled acetyl CoA and give rise to single labelled (M+1) compounds in the second turn. 17 
Second turn isotopologues were also observed when [1,2-13C]glucose was used as substrate 18 
(Figure 3D). It is important to note that only half of the pyruvate molecules are labelled from 19 
[1,2-13C]glucose and, therefore, the maximum enrichment levels will be half of those obtained 20 
from [1,6-13C]glucose. Alanine is obtained from pyruvate transamination and is generally 21 
considered to be a metabolite related to glycolysis. The expected isotopologue of [1,2-22 
13C]glucose is [1,2-13C]alanine. However, we observed M+1 alanine in addition to M+2 23 
labelled alanine (Figure 3D). This is evidence for the presence of partial pyruvate recycling, 24 
 18 
which can be performed via decarboxylation of malate or oxaloacetate into pyruvate 1 
(Sonnewald 2014).  2 
 3 
Acetate metabolism in oligodendrocytes 4 
Conversion of acetate into acetyl CoA is known to take place in astrocytes, but not in neurons 5 
(Sonnewald and Rae 2010). To investigate whether oligodendrocytes are able to convert 6 
acetate into acetyl CoA and oxidize it in the TCA cycle, cells were incubated with [1,2-7 
13C]acetate for 24h and the extra- and intracellular metabolites were analysed by GC-MS 8 
(Figure 3B, D). Both [1,2-13C]acetate and [1,2-13C]glucose identically yield [1,2-13C]acetyl 9 
CoA (Figure 3B). Overall, the extent of labelling from [1,2-13C]acetate was much lower than 10 
that from [1,2-13C]glucose. Enrichment of the most abundant metabolites citrate and 11 
glutamate from [1,2-13C]acetate was approximately half of enrichment obtained from [1,2-12 
13C]glucose; the less abundant metabolites aspartate and glutamine were poorly enriched. The 13 
abundance of M+1 isotopologues (typical of the second turn of the TCA cycle) derived from 14 
[1,2-13C]acetate was very low (Figure 3D), suggesting that acetate-derived acetyl CoA is 15 
metabolised in a different compartment than pyruvate-derived acetyl CoA. Alanine 16 
enrichment from [1,2-13C]acetate (albeit at low levels), confirms that oligodendrocytes have 17 
active partial pyruvate recycling, as observed in cells incubated with [1,2-13C]glucose. In the 18 
medium, labelling from [1,2-13C]acetate was only detectable in citrate, in which M+2 19 
amounted to 10 ± 2% (mean ± s.e.m., n=12). 20 
 21 
Glucose consumption and release of metabolites to the culture medium 22 
Analysis of glucose consumption and lactate release rates (Figure 3E-I,II) indicates that 23 
oligodendrocytes metabolise glucose to an extent comparable to astrocytes (3.2±0.06 24 
µmol/106 cells/24h; mean ± s.e.m.; n=6). However, oligodendrocytes release less lactate than 25 
 19 
astrocytes (5.3 ± 0.16 µmol/106 cells/24h; mean ± s.e.m.; n=6). Although glucose 1 
consumption in the presence of 4 mM [1-13C]lactate (Figure 3E-I) was increased, the net 2 
release of total lactate remained unchanged (Figure 3E-II). Due to the presence of [1-3 
13C]lactate in the culture medium, it was possible to distinguish between the uptake of [1-4 
13C]lactate and the release of endogenous (unlabelled) lactate (Figure 3E-III). This analysis 5 
showed that the presence of lactate in the medium increased the release of endogenous lactate 6 
(Figure 3E-III). The release of unlabelled lactate was at least 3-fold larger than the amount of 7 
[1-13C]lactate consumed. By comparing lactate release rates and glucose consumption rates it 8 
was possible to estimate the fraction of glucose metabolized to lactate, versus the oxidation of 9 
pyruvate in the mitochondria. In oligodendrocytes cultured with glucose alone, the ratio of 10 
lactate production to pyruvate oxidation was 60:40 (and 80:20 in astrocytes). In the presence 11 
of lactate, the ratio changed to 30:70, indicating increased mitochondrial activity. Figure 3C 12 
shows that the viability of cells was not affected by the presence of lactate. 13 
 Despite the substantial % enrichment of 13C in the above-mentioned amino acids 14 
observed in the cell extracts, only negligible release of alanine and glutamine was detected  15 
(data not shown).  16 
Pyruvate carboxylation in oligodendrocytes 17 
Pyruvate carboxylation is an important anaplerotic pathway known to operate in astrocytes 18 
but not in neurons (McKenna et al. 2012). The presence of this pathway was probed in mature 19 
oligodendrocytes by using either [1,2-13C]glucose or [1-13C]lactate (Figure 4). [1-13C]lactate 20 
is a valuable substrate for this purpose since only via pyruvate carboxylation the 13C label 21 
from [1-13C]lactate can be found in the TCA cycle intermediate citrate (PDH removes carbon 22 
number 1 from pyruvate generating unlabelled acetyl CoA, and therefore the 13C label is lost 23 
via PDH; Figure 4A). In order to evaluate the significance of pyruvate carboxylation in 24 
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oligodendrocytes, also astrocytes (the cells known to carboxylate pyruvate in the brain) were 1 
incubated with [1-13C]lactate. Both of these cell types were shown to oxidize lactate to a large 2 
extent in culture (Sanchez-Abarca et al. 2001). [1-13C]Pyruvate carboxylation was apparent in 3 
the labelling of citrate in the medium in both cell types (Figure 4B). However, in the cell 4 
extracts this was only evident in astrocytes. A possible explanation for the absence of 5 
intracellular citrate enrichment in oligodendrocytes is a potential compartmentation of 6 
pyruvate metabolism, which has also been shown for astrocytes and neurons (Bak et al. 2007; 7 
Bakken et al. 1997).  8 
To further investigate the presence of pyruvate carboxylation, oligodendrocytes were 9 
also incubated with medium containing [1,2-13C]glucose. The C-2 region of glutamate 10 
(around 55.5 ppm) in the 13C NMR spectrum of cell extracts was analysed to confirm the 11 
presence of pyruvate carboxylation (Figure 4C). From the scheme depicted in Figure 4C it 12 
emerges that only pyruvate carboxylation will lead to the formation of [2,3-13C]glutamate 13 
whereas [1,2-13C]glutamate (and [3-13C]glutamate, which is not shown) is formed from 14 
pyruvate dehydrogenation (and pyruvate carboxylation, if the label stays in the cycle for an 15 
additional turn). The spectrum shown in Figure 4C, which reflects the presence of [2,3-16 
13C]glutamate, indicates that oligodendrocytes carboxylate pyruvate.   17 
 21 
Discussion  1 
Although oligodendrocytes make up a significant proportion of brain cells, their metabolic 2 
properties remain largely unknown. In a recent review we have called for a systematic study 3 
of metabolic pathways in oligodendrocytes (Amaral et al. 2013). In the present work, we 4 
study aspects of glucose, lactate, and acetate metabolism in oligodendrocytes, and specifically 5 
address the activity of the PPP and whether oligodendrocytes are able to conduct anaplerotic 6 
and cataplerotic reactions based on carboxylation of pyruvate and decarboxylation of malate 7 
or oxaloacetate. 8 
 Primary rat OPCs were purified from perinatal rat mixed glial cultures (McCarthy and 9 
de Vellis 1980). This approach results in high yields of relatively pure (>93%) cultures. 10 
Culture of the O4+, A2B5+, O1-, CNP-, MBP- OPCs in Sato’s medium triggers a highly 11 
predictable series of morphological and transcriptional events and results in the formation of 12 
mature oligodendrocytes with complex branched processes and membrane sheets, which 13 
express late stage markers, including MBP. Although a significant proportion of cells 14 
(approximately 60%) reach a mature oligodendrocyte stage, the cultures also include late 15 
stage progenitors. Genomic studies comparing acutely isolated cells at distinct developmental 16 
stages with the culture system used in the present study confirmed that primary OPC cultures 17 
faithfully represent their in vivo counterparts (Dugas et al. 2006). 18 
 Our results demonstrate that oligodendrocytes have extensive glucose-derived 19 
metabolism. In fact, we found that the rate of glucose consumption in oligodendrocytes is 20 
comparable to the one in astrocytes. Although Sanchez-Abarca et al (2001) previously 21 
concluded that oligodendrocytes utilize more glucose than astrocytes, they also showed that 22 
oligodendrocytes metabolise a larger proportion of glucose via PDH than astrocytes. We 23 
obtained a similar result by comparing the ratios of lactate release to glucose consumption in 24 
both cell types. Furthermore, we observed that both glucose consumption and the proportion 25 
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of glucose-derived pyruvate metabolised in the mitochondria were increased in the presence 1 
of exogenous lactate. This suggests that lactate may act as metabolic activator in 2 
oligodendrocytes, fitting with the concept that lactate can act as signalling molecule (Rinholm 3 
and Bergersen 2014). Furthermore, our results confirm that oligodendrocytes are able to 4 
release substantial amounts of lactate in vitro as has been reported in vivo by Funfschilling et 5 
al. (2012). Also, it is possible that, at least, a proportion of the [1-13C]lactate taken up was 6 
oxidized for lipogenesis, as proposed by (Sanchez-Abarca et al. 2001). In spite of the 7 
presence of 4 mM exogenous lactate, a net production of lactate was observed indicating that 8 
glycolysis in oligodendrocytes is not inhibited by extracellular lactate.  9 
 The PPP is a glucose shunt, which is thought to be active in neurons and astrocytes 10 
(Almeida et al. 2002; Amaral et al. 2010; Bolanos and Almeida 2010; Brekke et al. 2012; 11 
Garcia-Nogales et al. 2003). Using 14C tracing techniques (Edmond et al. 1987) showed 12 
active PPP in oligodendrocyte lineage cells. Sanchez-Abarca et al. (2001) reported PPP 13 
activity in immature OPC cultures as being 2-fold higher than in astrocytes and 4-fold higher 14 
than in neurons. Our approach measured the contribution of the PPP to the synthesis of 15 
glycolytic intermediates and glutamate synthesis based on 13C-tracing techniques. In our 16 
study, the labelling of the glycolytic intermediates PEP and 3PG indicate that mature 17 
oligodendrocytes use approximately 10-15% of glucose in the PPP compared to glycolysis. 18 
These values are in the range of previously published data for cortical astrocyte cultures in a 19 
metabolic modelling study also using 13C-labelled substrates (Amaral et al. 2011a), which 20 
contrasts with the report by Sanchez-Abarca et al (2001). It is possible that our cultures 21 
contain more mature oligodendrocytes than those used by Sanchez-Abarca et al., and 22 
therefore have a lower PPP activity, more closely resembling the rate in astrocytes. On the 23 
basis of 14C tracing experiments, Sykes et al. reported that, although the PPP oxidizes only 24 
<3% of the glucose consumed, it produces more CO2 than the TCA cycle in primary 25 
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oligodendrocyte lineage cells, due to its close link to de novo synthesis of fatty acids and 1 
cholesterol (Sykes et al. 1986). Since we did not measure the contribution of glucose to lipid 2 
synthesis, it is possible that our approach underestimated the total use of glucose via the PPP.  3 
 For the first time, our experiments demonstrate that pyruvate generated from glucose 4 
via the PPP contributes to the synthesis of acetyl CoA for oxidation and generation of 5 
metabolites in the TCA cycle in oligodendrocytes. We found that approximately 10% of the 6 
glutamate produced derives from glucose metabolized in the PPP. Estimation of the PPP 7 
activity on the basis of glutamate isotopomers indicated that the PPP accounted for 8 
approximately 6% of glucose metabolism in cortical neurons and approximately 4% in 9 
cerebellar neurons (Brekke et al. 2012). Similar to reports in neurons (Brekke et al. 2012), we 10 
found that oligodendrocytes incorporate 13C label in glutamate produced by [1,2-13C]glucose 11 
metabolism via the PPP.  12 
 The PPP may also play a role in diseases that affect oligodendrocytes. E.g. increased 13 
activity of the transaldolase, an enzyme which forms part of the non-oxidative branch of the 14 
PPP and is involved in lipid and nucleotide synthesis, has been reported in oligodendrocytes 15 
in brains of MS patients, compared to healthy controls (Banki et al. 1994). NADPH produced 16 
in the PPP is fundamentally important for the synthesis of glutathione, which is thought to 17 
protect myelin sheaths from oxidative stress. Banki and colleagues proposed that auto-18 
antibodies against transaldolase found in MS patients, may cause destruction of 19 
oligodendrocytes via depletion of transaldolase. Altered PPP activity was also reported in a 20 
study of patients that suffered a traumatic brain injury (TBI) (Dusick et al. 2007). It is 21 
possible that, at least, a proportion of the PPP alterations observed in the study by Dusick et al 22 
(2007) could be linked to the extensive demyelination that is thought to occur in TBI patients 23 
(Armstrong et al. 2015).  24 
 24 
 Using different forms of 13C labelled glucose we demonstrate that our cultures also 1 
exhibit a high rate of mitochondrial metabolism, as previously suggested by Sanchez-Abarca 2 
et al. (2001). Whereas functional mitochondria seem to be important for OPC differentiation 3 
(Schoenfeld et al. 2010; Ziabreva et al. 2010), it was recently proposed that myelinating 4 
oligodendrocytes are not dependent on mitochondrial activity in vivo (Funfschilling et al. 5 
2012).  The most likely explanation for the discrepancy between the high mitochondrial 6 
demands of our cultures and the findings in vivo is the significant presence of pre-myelinating 7 
(MBP-negative) OPCs that have not yet reached fully mature stages in vitro. Our data thus 8 
may reflect the prominent role of oxidative metabolism at the late stages of OPC 9 
differentiation, including the pre-myelinating and early myelinating stages. 10 
 Another important question with respect to mitochondrial metabolism in 11 
oligodendrocytes is whether they can replenish TCA cycle intermediates via anaplerosis. It is 12 
well established that neurons depend on astrocytes for replenishing their TCA cycle 13 
intermediates. As neurons cannot carboxylate pyruvate, external TCA cycle intermediates are 14 
required for the synthesis of amino acid neurotransmitters (McKenna et al. 2012). Whether 15 
and to which extent oligodendrocytes are self-sufficient with respect to the production of 16 
anaplerotic substrates remained unknown. By incubating cells with [1,2-13C]glucose we found 17 
that pyruvate carboxylation indeed takes place in oligodendrocytes as shown by the 18 
production of [2,3-13C]glutamate. This was further confirmed by label incorporation in citrate 19 
in the medium of cells incubated with [1-13C]lactate, which is only possible via pyruvate 20 
carboxylation. Comparable label incorporation from [1-13C]lactate was found in citrate in the 21 
medium of astrocyte cultures. This suggests that lactate is metabolised in a similar way in the 22 
TCA cycle of both cell types. However, it is possible that a fraction of the lactate taken up by 23 
our cultures was used for lipogenesis (Sanchez-Abarca et al. 2001). It must also be noted that 24 
the overall contribution of pyruvate carboxylation to oligodendrocyte and astrocyte 25 
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metabolism is underestimated in the experiments based on [1-13C]lactate metabolism because 1 
[1-13C]pyruvate derived from [1-13C]lactate competes with unlabelled pyruvate derived from 2 
glucose, which is also present in the incubation medium.  3 
Pyruvate can be carboxylated to oxaloacetate by PC or to malate and NADP+ by 4 
malic enzyme. Whether PC or malic enzyme is responsible for pyruvate carboxylation in 5 
oligodendrocytes remains to be established. Murin et al. (2009) reported PC expression in 6 
cultured oligodendroglia. Whether oligodendrocytes express malic enzyme remains unknown. 7 
In neurons and astrocytes, malic enzyme only contributes to pyruvate production (McKenna 8 
et al. 2000; McKenna et al. 1995). However, PC is thought to be the most important 9 
anaplerotic enzyme in the brain (Patel 1974). Irrespective of which enzyme is responsible for 10 
pyruvate carboxylation, the detection of carboxylation (and thus anaplerosis) has 11 
consequences for oligodendrocyte metabolism. If oligodendrocytes (similarly to neurons) 12 
were not capable of anaplerosis they would depend on the provision of glutamine by 13 
astrocytes, which have a net production of glutamine via pyruvate carboxylation (Gamberino 14 
et al. 1997; Waagepetersen et al. 2001). 15 
An alternative route to replenish the TCA cycle in oligodendrocytes is to use 16 
aspartate, liberated from N-acetyl aspartate (NAA), which in turn is supplied by neurons 17 
(Moffett et al. 2007). However, aspartate released by NAA hydrolysis in oligodendrocytes 18 
could potentially be sent back to neurons, thus avoiding the depletion of anaplerotic substrates 19 
in neurons (NAA synthesis in neurons is dependent on glutamine entry from astrocytes). Our 20 
results indicate that oligodendrocytes are capable of anaplerosis, which suggests that they are 21 
potentially independent of astrocytic pyruvate carboxylation. Whether the level of anaplerosis 22 
in oligodendrocytes is sufficient to meet their entire requirements is not known at present. It is 23 
also unclear whether aspartate is shuttled back to neurons or whether it is metabolized in 24 
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oligodendrocytes. Both possibilities have previously been suggested but evidence is lacking 1 
(Baslow and Guilfoyle 2006; Moffett et al. 2007).  2 
 Acetyl CoA is an essential molecule in the TCA cycle. Most acetyl CoA derives from 3 
pyruvate via PDH. However, oligodendrocytes are known to express the enzyme 4 
aspartoacylase, which catalyzes the hydrolysis of NAA into aspartate and acetate (Moffett et 5 
al. 2011). NAA-derived acetate significantly contributes to myelin lipid synthesis in the CNS 6 
(Chakraborty et al. 2001) and is also thought to support oxidative metabolism during 7 
myelination (Francis et al. 2012). Furthermore, oligodendrocytes express acetyl CoA 8 
synthetase-1, which  catalyzes the synthesis of acetyl coenzyme A from acetate and coenzyme 9 
A, indicating that acetate may contribute to lipid synthesis, especially during postnatal brain 10 
development (Ariyannur et al. 2010). So far only astrocytes were shown to convert acetate 11 
into acetyl CoA whereas neurons do not seem able to do so (Muir et al. 1986; Sonnewald et 12 
al. 1993a). Consequently, acetate has been used extensively to assess astrocyte metabolism in 13 
the context of astrocytic-neuronal interactions in vivo (e.g. Melo et al. 2005; Morken et al. 14 
2014; Nilsen et al. 2014), in neurospheres (Sa Santos et al. 2011) and in culture (Sonnewald et 15 
al. 1993a). However, potential metabolic contributions from oligodendrocytes were not 16 
considered in these studies. The present work demonstrates that mature oligodendrocyte 17 
cultures are able to convert acetate into acetyl CoA and oxidize it in the mitochondria as 18 
shown by the incorporation of 13C label from [1,2-13C]acetate into the TCA cycle 19 
intermediates malate and citrate and the amino acids glutamate and glutamine. Labelling from 20 
[1,2-13C]acetate was not as pronounced as labelling from [1,2-13C]glucose but, nevertheless, 21 
significant and comparable to that observed in astrocytes (data not shown). However, 22 
astrocytes label glutamine extensively from 13C-labelled acetate (Hassel et al. 1995), whereas 23 
oligodendrocytes do not. Surprisingly, we found that alanine was also labelled from [1,2-24 
13C]acetate, and that alanine M+1 enrichment was detected in oligodendrocytes incubated 25 
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with [1,2-13C]glucose. Both isotopologues of alanine could not have been produced without 1 
the participation of the TCA cycle and malic enzyme or pyruvate kinase (PK) and 2 
phosphoenolpyruvate carboxykinase (PEPCK) (Cruz et al. 1998). This indicates that pyruvate 3 
recycling, a catabolic pathway (Amaral et al. 2011b; Cerdan et al. 1990; Haberg et al. 1998; 4 
Kunnecke et al. 1993; Olstad et al. 2007), is not only active in astrocytes and neurons but also 5 
in oligodendrocytes.  6 
Conclusion 7 
Our results show that oligodendrocyte lineage cells at late stages of differentiation are 8 
metabolically active cells and have distinct metabolic properties. We found that the cells were 9 
able to conduct all the metabolic functions that were investigated and, therefore, demonstrate 10 
a high degree of cellular independence. Figure 5 summarizes the findings of the present series 11 
of experiments and integrates our data with the known pathways linking astroglial and 12 
neuronal metabolism. Our results indicate that metabolic functions of oligodendroglia need to 13 
be considered in studies investigating glucose metabolism in CNS tissue or whole brain 14 
studies. This work reinforces the emerging role of oligodendrocyte metabolism with respect 15 
to neuronal-glial interactions. 16 
 17 
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Figure legends 1 
Figure 1 - Purity of the primary cultures of rat oligodendrocytes. Oligodendrocyte 2 
precursor cells were isolated from mixed glia cultures and cultured in Sato’s medium + 0.05% 3 
FCS to induce differentiation. At day 1 of differentiation, more than 93% of the cells 4 
expressed the oligodendroglial lineage marker O4 (A) and at 5 days of differentiation 5 
approximately 65% of the cells expressed myelin basic protein (MBP), a marker of mature 6 
oligodendrocytes (B). Scale bars, 50 µm. 7 
 8 
Figure 2 - Evidence of PPP activity in mature oligodendrocytes in culture after 9 
incubation with [1,2-13C]glucose. Labelling patterns derived from [1,2-13C]glucose 10 
metabolism via glycolysis (A) and the pentose phosphate pathway (PPP) (B). The % 11 
enrichment of 13C in M+1 and M+2 isotopologues for 3PG and PEP was determined using 12 
GC-MS analysis of cell extracts after 24h incubation with [1,2-13C]glucose. The ratio shown 13 
in (C) between M+1 (labelling from the PPP) and M+2 (labelling from glycolysis) enables to 14 
estimate the contribution of the PPP versus glycolysis to the formation of the glycolytic 15 
intermediates 3PG and PEP in mature oligodendrocyte (mean ± s.e.m.; n=3). (D) 13C nuclear 16 
magnetic resonance spectrum of a cell extract from cultures incubated in medium containing 17 
[1,2-13C]glucose for 24 h. The C-4 region of glutamate at 34.5 ppm (GLU) is shown. The 18 
doublet peak represents [4,5-13C]glutamate ([4,5-13C]GLU) which derives from glucose 19 
metabolism via glycolysis only.  The singlet peak corresponds to [4-13C]glutamate ([4-20 
13C]GLU) which is produced after glucose metabolism via the PPP. Abbreviations: 3PG, 3-21 
phosphoglycerate; GLU, glutamate; PEP, phosphoenolpyruvate; PDH, pyruvate 22 
dehydrogenase; M+1, parent ion with one 13C atom; M+2, parent ion with two 13C atoms.  23 
 24 
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Figure 3. Evidence of high TCA cycle activity and acetate metabolism in mature 1 
oligodendrocytes in culture. Oligodendrocytes were differentiated for 5 days and incubated 2 
for 24h in medium containing [1,6-13C]glucose (A), [1,2-13C]glucose (B), or [1,2-13C]acetate 3 
(B), followed by GC-MS analysis of samples of cell culture medium and cell extracts. A and 4 
B describe the labelling patterns deriving from the metabolism of these 13C-labelled 5 
substrates. The isotopologues formed in the second turn of the TCA cycle result from 6 
condensation of labelled oxaloacetate (OAA) with labelled or unlabelled acetyl CoA. (C) 7 
Quantification of TUNEL positive/total cell number (given by DAPI staining) in cells 8 
incubated with glucose alone (mean ± s.e.m., n=12), glucose and lactate (mean ± s.e.m., 9 
n=10) or acetate (mean ± s.e.m., n=8); (D) % enrichment of 13C in intracellular alanine and 10 
TCA cycle-related metabolites derived from each of the substrates (mean ± s.e.m., n=8 for 11 
[1,6-13C]glucose, mean ± s.e.m., n=6 for [1,2-13C]glucose and mean ± s.e.m., n=12 for [1,2-12 
13C]acetate). (E) Glucose (I) and lactate (II) net change in the medium in experiments 13 
performed in the presence of glucose alone or glucose + [1-13C]lactate. For the experiment 14 
where [1-13C]lactate was used, the net change of 13C-labelled and unlabelled lactate is shown 15 
(III) (mean ± s.e.m., n=9). # - significantly different from the glucose + [1-13C]lactate group 16 
(p<0.05, Student’s t test). 17 
 Abbreviations: ALA, alanine; ASP, aspartate; CIT, citrate; GLN, glutamine; GLU, 18 
glutamate; MAL, malate; PYR, pyruvate; M+1, parent ion with one 13C atom; M+2, parent 19 
ion with two 13C atoms; M+3, parent ion with three 13C atoms; M+4, parent ion with four 13C 20 
atoms. *The enrichment detected in alanine derives directly from 13C-labelled pyruvate and 21 
not from the TCA cycle when [1,6-13C]glucose is the precursor. When [1,2-13C]glucose is 22 
used, M+2 is not derived from the TCA cycle but M+1 alanine is. When [1,2-13C]acetate is in 23 
the medium, both alanine isotopologues are derived from the TCA cycle 24 
 25 
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Figure 4 - [1-13C]lactate metabolism and evidence for pyruvate carboxylation in 1 
oligodendrocytes. (A) Labelling patterns resulting from the metabolism of [1-13C]lactate (13C 2 
atoms are identified in red): [1-13C]lactate (LAC) is converted into [1-13C]pyruvate, which 3 
can be converted into acetyl-CoA via pyruvate dehydrogenase (PDH) or into [1-4 
13C]oxaloacetate (OAA) via pyruvate carboxylase (PC). The first carbon of pyruvate is lost in 5 
its conversion to acetyl-CoA via PDH. Therefore, the 13C label can only be observed 6 
downstream of pyruvate if PC is active. [1-13C]oxaloacetate can condense with acetyl-CoA to 7 
form [6-13C]citrate which also leads subsequently to the formation of unlabelled α-8 
ketoglutarate by loss of carbon 6. (B) The % enrichment of 13C in citrate indicates the 9 
contribution of pyruvate carboxylation to citrate formation from [1-13C]lactate. The % of M+1 10 
citrate was assessed using GC-MS in samples of cell extracts and culture medium from 11 
differentiated oligodendrocytes and also in cultures of cortical astrocytes after 24h of 12 
incubation with [1-13C]lactate (oligodendrocytes - mean ± s.e.m., n=9; and astrocytes - mean 13 
± s.e.m., n=6). (C) Contribution of pyruvate carboxylation to glutamate synthesis from [1,2-14 
13C]glucose. Oligodendrocytes were incubated in medium containing [1,2-13C]glucose for 15 
24h, extracted, and analysed using 13C-magnetic resonance spectroscopy for the presence of 16 
isotopologues of glutamate formed via pyruvate carboxylation. The C-2 region of glutamate 17 
(GLU) at 55.5 ppm is shown. The doublet representing [2,3-13C]glutamate is formed via 18 
pyruvate carboxylation and the doublet representing [1,2-13C]glutamate is formed via 19 
pyruvate dehydrogenation. Abbreviations: ASP, aspartate; GLN, glutamine; GLU, glutamate; 20 
MAL, malate; OAA, oxaloacetate; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; 21 
PYR, pyruvate. 22 
 23 
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Figure 5 – Integration of metabolic pathways operating in oligodendrocytes in the 1 
context of metabolic interactions with astrocytes and neurons/axons. The pathways 2 
investigated in the present study are highlighted in red in the oligodendrocyte: glucose is 3 
taken up and subsequently metabolized either via glycolysis only (1) or also via the pentose 4 
phosphate pathway (2); the resulting pyruvate (PYR) produced can be reduced to lactate 5 
(LAC) (3) which can be released and taken up by cells with lower lactate concentration. 6 
Moreover, pyruvate can be carboxylated via pyruvate carboxylase (PC) or malic enzyme 7 
(ME) into oxaloacetate (OAA) or malate (MAL) or enter the TCA cycle after being converted 8 
to acetyl CoA (Ac-CoA) via pyruvate dehydrogenase (PDH) (4). The TCA cycle intermediate 9 
α-ketoglutarate (α-KG) gives rise to glutamate (GLU) and, subsequently, glutamine (GLN), 10 
but none of these aminoacids appear to be significantly released. Pyruvate can be further 11 
completely oxidized if it is decarboxylated via ME, a pathway called pyruvate recycling (5), 12 
which also seems to be present in this cell type. Oligodendrocytes can also metabolise acetate 13 
into acetyl CoA (6) that can be then incorporated into lipids or oxidized in the TCA cycle.  14 
 15 
Supplementary Figure 1 – Time courses of [1,6-13C]glucose-derived percent enrichment of 16 
13C in intracellular alanine, citrate, malate, aspartate, glutamate and glutamine after 0, 4, 8 and 17 
24h of incubation (n=12). M+1, parent ion with one 13C atom; M+2, parent ion with two 13C 18 
atoms; M+3, parent ion with three 13C atoms. For labelling patterns see Figure 3A. 19 
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